Research programme: proto oncogene protein c-myc inhibitors - Peptomyc

Drug Profile

Research programme: proto oncogene protein c-myc inhibitors - Peptomyc

Alternative Names: OMO-101; OMO-103; Omomyc-based cell penetrating peptides - Peptomyc; Omomyc-CPP

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Peptomyc; Vall d-Hebron Research Institute
  • Class Antineoplastics; Peptides
  • Mechanism of Action Proto oncogene protein c-myc inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 May 2017 Research programme: proto oncogene protein c-myc inhibitors - Peptomyc is available for licensing as of 11 May 2017. http://www.peptomyc.com/
  • 11 May 2017 Peptomyc plans a phase I/II trial in Glioblastoma (Peptomyc pipeline, May 2017)
  • 01 Jan 2016 Preclinical trials in Cancer in Spain (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top